Introduction
Autologous hematopoietic SCT provides hematopoietic support after high-dose chemotherapy in patients with multiple myeloma (MM), intermediate-grade non-Hodgkin's lymphoma and Hodgkin's disease. A standard approach to hematopoietic stem cells mobilization (SCM) is the use of granulocyte colony-stimulating factor (G-CSF). Combining G-CSF with high-dose chemotherapy, such as CY, etoposide or carmustine, greatly enhances the mobilization of stem cells compared with G-CSF alone.
1,2 These cytotoxic agents may potentially have the added benefit of decreasing tumor load. SCM using chemotherapy combined with G-CSF, has limitations including toxicity, mobilization failure and includes resource utilization owing to the unpredictability of collections and hospital admissions. Although there is a minimal level of CD34 þ cell collection considered necessary for autologous hematopoietic SCT (that is, 2 Â 10 6 cells/kg), most centers consider a cell dose of X5 Â 10 6 CD34 þ cells/kg has been associated with shorter hematopoietic recovery time and reduced costs. 3, 4 In addition to the successful mobilization of stem cells, important clinical considerations related to the outcomes of chemotherapy include the number of days required to collect the minimal cell dose, optimal cell collection thresholds and the predictability of initiating leukapheresis. All of these factors contribute to the costs of mobilization, which include not only the cost of the drug, but the costs of remobilization in patients who fail to achieve target yields, complications such as adverse events and transfusions and predictability issues (weekend leukapheresis, peripheral blood CD34 þ cell monitoring). 4, 5 Towards understanding the impact of SCM treatments on outcomes that will help in making informed decisions about the best mobilization practices, we examined the extent to which mobilization with CY plus G-CSF (CY þ G) was associated with a clinically ideal outcome, adverse events and cost.
Patients and methods
A retrospective analysis of electronic medical records was conducted on all adult patients diagnosed with Hodgkin's disease, non-Hodgkin's lymphoma and MM, undergoing first autologous hematopoietic SCT at Vanderbilt University Medical Center from 1/2004 to 3/2008 (N ¼ 236) who received high-dose CY þ G. All patients underwent SCM and if eligible, subsequent transplant on standard of care protocols or protocols approved by IRB. All were admitted to Vanderbilt University Hospital, where IRB approval for this retrospective study was obtained.
Stem cell mobilization
CY was administered at 3 gm/m 2 and G started the next day (10 mcg/kg) for at least 10 days, with a planned first day of collection on day 11. Dose escalations of G were per standard institutional protocol. There were no differences in dose-escalation algorithms based on disease diagnosis. All patients received subsequent clinical care for CY-related side effects at the transplant center, either as outpatients or inpatients. Leukapheresis was initiated if peripheral blood CD34 þ levels were X15 cells/mL. Patients who failed to achieve sufficient blood levels for leukapheresis on CY þ G were treated on a case-by-case basis; interventions included autologous BM harvest, attempt at remobilization using plerixafor plus G, allogeneic transplant, or standard chemotherapy.
Definitions
Data on clinical outcomes and adverse events were abstracted from electronic medical records. Adverse events included fever, febrile neutropenia, line infection, gastrointestinal toxicity, bone pain, volume overload and hemorrhagic cystitis. An ideal outcome was defined as X2 Â 10 6 CD34 þ cells/kg collected on the planned day of collection in 1 or 2 leukapheresis without a preceding negative event that lead to additional evaluation and management in clinic or as an inpatient.
Costs calculations
The cost of drugs (CY and G), leukapheresis, product processing and clinical events, were reported based on Medicare part-B physician, laboratory and ancillary fee schedule. Costs of management of these adverse events either in the outpatient or inpatient were computed by analyzing five patient records per clinical event and applying it to the entire study cohort. Pre-leukapheresis costs were defined as all costs incurred from start of CY until start of leukapheresis. Peri-leukapheresis costs included costs of leukapheresis, processing of product and costs associated with cryopreservation. Table 1 summarizes the cost details that were applied to the cohort. Costs of subsequent care after a failed SCM were not included in this study.
Statistical methods
Descriptive statistics were reported as means and s.d. when normally distributed, and medians accompanied by interquartile ranges (IQR) when non-normally distributed. Group comparisons employed parametric tests such as t-tests and ANOVA for normally distributed continuous data. Non-normally distributed data were analyzed using w 2 , Wilcoxon, or Kruskal-Wallis tests. Data were analyzed using SPSS (IBM, Chicago, IL, USA) and R statistical software packages (R Foundation for Statistical Computing, Vienna, Austria). An alpha of 0.05 was set as the threshold for statistical significance. Table 2 summarizes the patient characteristics. Of the 236 patients who received CY þ G, 121 (51%) had MM and 115 (49%) had lymphoma.
Results

Patient characteristics
Mobilization efficacy with CY þ G Table 2 summarizes the details of mobilization characteristics of the study cohort. Before high-dose CY, median WBC was 5.3 Â 10 9 /L (IQR, 4.2-6.6) and median neutrophil count was 3.3 Â 10 9 /L (IQR, 2.4-4.2). Of 236 patients who received CY þ G, 213 patients (90%) started leukapheresis and 23 patients (10%) had failure of SCM. Of the patients who had failure of SCM (19-lymphoma, 4-myeloma), 22 patients did not undergo any apheresis and one patient yielded o2 Â 10 6 CD34 þ cells/kg. SCM was delayed (range, 1-7 days) beyond the planned day in 42 patients (18%). Patients with lymphoma had a higher incidence of delay in SCM compared with myeloma patients (30 versus 6%, Po0.001).
The final median CD34 þ cell dose harvested from CY þ G patients was 8.1 Â 10 6 CD34 þ /kg (IQR, 3.8 Â 10 6 , 14.0 Â 10 6 ). Patients with a diagnosis of MM yielded more CD34 þ cells/kg than patients with lymphoma (11.6 Â 10 6 versus 3.9 Â 10 6 , Po0.001). Six patients (2.8%) yielded o2 Â 10 6 CD34 þ /kg. The median number of pheresis was 1 (range, 0-4) with 38 (16%), and 10 (4%) requiring 2 and 3 pheresis, respectively. In all, 158 patients yielded 42 Â 10 6 CD34 þ cells/kg in 1 apheresis; 38 patients underwent 2 apheresis (myeloma ¼ 20, lymphoma ¼ 18) and 31 yielded 42 Â 10 6 CD34 þ cells/kg. Most of the myeloma patients (92, 79%) underwent 1 leukapheresis, with 20 (17%), and 5 (4%) patients requiring 2 and 3 leukapheresis, respectively. Only 73 patients (60%) with myeloma yielded the target cell dose of X6 Â 10 6 CD34 þ cells/kg. The target cell dose in MM patients was collected in 1, 2, or 3 pheresis in 57 (78%), 14 (19%) , and 2 (3%), respectively.
In the lymphoma cohort, the number of patients undergoing 1, 2, 3 and 4 leukapheresis were 72 (75%), 18 (19%), 3 (5%) and 1 (1%), respectively. In all, 78 patients (68%) yielded the target cell dose of X2 Â 10 6 CD34 þ cells/kg. The target cell dose was collected in 1, 2, 3 or 4 pheresis in 60 (77%), 12 (15%), 5 (7%) and 1 (1%) patients, respectively.
An ideal outcome (defined by collection of target cell dose in 1 or 2 leukapheresis without any delay and a preceding clinical event) was seen in a total of 50 patients (20%), including 30 (23%) with MM and 20 (18%) with lymphoma (P40.05). Adverse clinical events associated with CY þ G patients were statistically and significantly higher among patients with a non-ideal outcome, as would be expected owing to the nature to the definition of ideal outcome (Table 3) .
Cost analysis
Cost data is summarized in Table 4 . Median (IQR) total cost of CY þ G SCM was $10 605 ($9230-$14 540). For all patients treated with CY þ G, ideal outcomes were associated with lower costs compared with patients with non-ideal outcomes, (median (IQR), $9914 ($8743-$11 168) versus $11 232 ($9292-$15 518), respectively, Po0.001). There was no difference in costs associated with ideal outcome patients based on diagnosis (myeloma, median (IQR) was $9796 ($8480-$12 056) versus lymphoma, $9968 ($8953-$10 396), P40.05). The median (IQR) cost of nonideal outcome was higher among lymphoma patients, $12 293 ($9578-$16 268) compared with myeloma patients, $10 388 ($9355-$14 360), (P ¼ 0.04) (Figure 1 ).
Discussion
Our data showed that only 20% of patients had ideal outcomes after CY þ G SCM. Costs associated with a nonideal outcome were significantly higher compared with an ideal outcome, suggesting that a treatment strategy that improves the proportion of ideal outcomes could result in substantial cost savings. We found that pre-apheresis costs were higher if SCM was not achieved, and costs were higher among lymphoma patients when compared with MM patients when ideal outcomes were not achieved.
Our study supports the results of previous studies that found less than optimal stem cell collections using G alone for SCM was associated with increased resource utilization. 6 Although SCM using CY þ G is among the standards of care for the treatment of lymphoma and MM, our study suggests that there is the potential for alternative strategies to further improve outcomes with the adoption of cost-effective treatments. CY has the added potential of decreasing tumor load while aiding SCM. Among possible treatment options for SCM, plerixafor, a small molecule in a new class of agent known as CXCR4 antagonists, was recently approved to enhance the mobilization of PBSCs. 7 When combined with G-CSF, plerixafor results in significantly more patients reaching optimal CD34 þ collection target levels for transplantation compared with placebo plus G-CSF in patients with MM 8 and non-Hodgkin's lymphoma. 9 As novel agents are typically associated with higher costs than long-standing chemotherapy regimens typically used with G-CSF, plerixafor use may be reserved for patients who fail mobilization on first-line chemotherapy plus G-CSF. In an open-label phase 2 study, plerixafor significantly improved SCM in proven poor or predicted poor mobilizing group of patients with MM. 10 The safety profile of plerixafor is generally comparable to G-CSF alone, with most adverse events such as gastrointestinal tract effects being transient. Evidence comparing the clinical outcomes and cost of conventional chemotherapy plus G-CSF and plerixafor plus G-CSF (P þ G) has only begun to emerge. 11, 12 When P þ G was used for SCM in myeloma, a target cell dose of 46 Â 10 6 CD34 þ cells/kg was reached in 1, 2, and 3 leukapheresis in 54, 24 and 9% of patients, respectively. Similarly, using P þ G for SCM in lymphoma, a target cell dose of 42 Â 10 6 CD34 þ cells/kg is reached in 1, 2, and 3 leukapheresis in 56, 25 and 7% of patients, respectively. Adverse events in myeloma patients after P þ G SCM were diarrhea (18%), nausea (16%), emesis (5%) and bone pain (9%). 8 Adverse events reported for lymphoma patients included diarrhea (38%), nausea (17%) and abdominal pain (6%). 9 A recent study using a Monte Carlo simulations of 1000 cases suggested that P þ G may be more cost-effective than CY þ G for autologous SCM for most patients with non-Hodgkin's lymphoma. 13 The outcomes reported in this study are based on observational data from a single institution, which may have limited generalizability to other practice settings. Another limitation of our study is that no direct Table 3 Clinical characteristics of patients with ideal outcome and non-ideal outcome comparison is made with other regimens in the analysis. Although eventual success in adequate stem cell collection is realized in most patients with CY þ G, the proportion of patients achieving an 'ideal outcome' as defined a priori remained low. Any intervention to increase the incidence of 'ideal outcome' would not only positively impact patient care, but could potentially result in more cost-effectiveness. As the data for treatment outcomes were extracted from actual clinical practice, this data can also be considered strength of the study. Conventional high-dose CY (3 g/m 2 ) was practiced by our institution, but some studies suggest low rates of adverse events and less toxicity may produce similar levels of efficacy using lower doses of CY. 14, 15 Costs reported in our study may be lower than at other centers owing to the outpatient transplant operational model at our institute. Cost estimates did not take into account costs associated with operational planning and predictability of the date of SCM and the effects of mobilization failure leading to other alternative clinical approaches including allo-SCT (n ¼ 6). Higher cost associated with non-ideal outcomes in our analysis is expected to be owing to increased negative events that lead to additional evaluation and management in clinic or as an inpatient. The impact of non-ideal outcomes and adverse events on costs and quality of life were not evaluated, and is likely be higher in this group of patients.
In summary, SCM with CY þ G was associated with an ideal clinical outcome in less than 25% of patients with lymphoma and MM, and ideal SCM outcomes were associated with lower costs than non-ideal outcomes. Treatment protocols that increase the number of patients with ideal outcomes may not only improve clinical outcomes but also economic outcomes of cancer care. With the growing importance of managing limited health care resources, it may be prudent to compare the pharmacoeconomics of CY þ G and P þ G in a prospective randomized study and to examine specific patients groups in whom P þ G may have a higher incidence of ideal clinical outcomes without increasing costs.
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